Immune responsiveness against allogeneic platelet transfusions is determined by the recipient's major histocompatibility complex class II phenotype
Ebrahim Sayeh
From the Department of Laboratory Medicine and Pathobiology, St. Michael's Hospital; the Departments of Pharmacology, Medicine, and Laboratory Medicine and Pathobiology, University of Toronto, Canadian Blood Services; and the Toronto Platelet Immunobiology Group, Toronto, Ontario, Canada.
Search for more papers by this authorRukshana Aslam
From the Department of Laboratory Medicine and Pathobiology, St. Michael's Hospital; the Departments of Pharmacology, Medicine, and Laboratory Medicine and Pathobiology, University of Toronto, Canadian Blood Services; and the Toronto Platelet Immunobiology Group, Toronto, Ontario, Canada.
Search for more papers by this authorEdwin R. Speck
From the Department of Laboratory Medicine and Pathobiology, St. Michael's Hospital; the Departments of Pharmacology, Medicine, and Laboratory Medicine and Pathobiology, University of Toronto, Canadian Blood Services; and the Toronto Platelet Immunobiology Group, Toronto, Ontario, Canada.
Search for more papers by this authorHoang Le-Tien
From the Department of Laboratory Medicine and Pathobiology, St. Michael's Hospital; the Departments of Pharmacology, Medicine, and Laboratory Medicine and Pathobiology, University of Toronto, Canadian Blood Services; and the Toronto Platelet Immunobiology Group, Toronto, Ontario, Canada.
Search for more papers by this authorAlan H. Lazarus
From the Department of Laboratory Medicine and Pathobiology, St. Michael's Hospital; the Departments of Pharmacology, Medicine, and Laboratory Medicine and Pathobiology, University of Toronto, Canadian Blood Services; and the Toronto Platelet Immunobiology Group, Toronto, Ontario, Canada.
Search for more papers by this authorJohn Freedman
From the Department of Laboratory Medicine and Pathobiology, St. Michael's Hospital; the Departments of Pharmacology, Medicine, and Laboratory Medicine and Pathobiology, University of Toronto, Canadian Blood Services; and the Toronto Platelet Immunobiology Group, Toronto, Ontario, Canada.
Search for more papers by this authorCorresponding Author
John W. Semple
From the Department of Laboratory Medicine and Pathobiology, St. Michael's Hospital; the Departments of Pharmacology, Medicine, and Laboratory Medicine and Pathobiology, University of Toronto, Canadian Blood Services; and the Toronto Platelet Immunobiology Group, Toronto, Ontario, Canada.
John W. Semple, PhD, Department of Laboratory Medicine and Pathobiology, St. Michael's Hospital, 30 Bond St. Toronto, Ontario, Canada, M5B 1W8; e-mail: [email protected].Search for more papers by this authorEbrahim Sayeh
From the Department of Laboratory Medicine and Pathobiology, St. Michael's Hospital; the Departments of Pharmacology, Medicine, and Laboratory Medicine and Pathobiology, University of Toronto, Canadian Blood Services; and the Toronto Platelet Immunobiology Group, Toronto, Ontario, Canada.
Search for more papers by this authorRukshana Aslam
From the Department of Laboratory Medicine and Pathobiology, St. Michael's Hospital; the Departments of Pharmacology, Medicine, and Laboratory Medicine and Pathobiology, University of Toronto, Canadian Blood Services; and the Toronto Platelet Immunobiology Group, Toronto, Ontario, Canada.
Search for more papers by this authorEdwin R. Speck
From the Department of Laboratory Medicine and Pathobiology, St. Michael's Hospital; the Departments of Pharmacology, Medicine, and Laboratory Medicine and Pathobiology, University of Toronto, Canadian Blood Services; and the Toronto Platelet Immunobiology Group, Toronto, Ontario, Canada.
Search for more papers by this authorHoang Le-Tien
From the Department of Laboratory Medicine and Pathobiology, St. Michael's Hospital; the Departments of Pharmacology, Medicine, and Laboratory Medicine and Pathobiology, University of Toronto, Canadian Blood Services; and the Toronto Platelet Immunobiology Group, Toronto, Ontario, Canada.
Search for more papers by this authorAlan H. Lazarus
From the Department of Laboratory Medicine and Pathobiology, St. Michael's Hospital; the Departments of Pharmacology, Medicine, and Laboratory Medicine and Pathobiology, University of Toronto, Canadian Blood Services; and the Toronto Platelet Immunobiology Group, Toronto, Ontario, Canada.
Search for more papers by this authorJohn Freedman
From the Department of Laboratory Medicine and Pathobiology, St. Michael's Hospital; the Departments of Pharmacology, Medicine, and Laboratory Medicine and Pathobiology, University of Toronto, Canadian Blood Services; and the Toronto Platelet Immunobiology Group, Toronto, Ontario, Canada.
Search for more papers by this authorCorresponding Author
John W. Semple
From the Department of Laboratory Medicine and Pathobiology, St. Michael's Hospital; the Departments of Pharmacology, Medicine, and Laboratory Medicine and Pathobiology, University of Toronto, Canadian Blood Services; and the Toronto Platelet Immunobiology Group, Toronto, Ontario, Canada.
John W. Semple, PhD, Department of Laboratory Medicine and Pathobiology, St. Michael's Hospital, 30 Bond St. Toronto, Ontario, Canada, M5B 1W8; e-mail: [email protected].Search for more papers by this authorSupported by a grant from the Canadian Blood Services R & D Fund (XT0008). E.S. was a recipient of a Post Doctoral Fellowship from the Canadian Blood Services.
Abstract
BACKGROUND: Immunoglobulin G (IgG) anti-platelet (PLT) immunity has been shown to be initiated by indirect allorecognition where recipient T cells recognize donor PLT antigens presented by class II molecules encoded by the major histocompatibility complex (MHC) on recipient antigen-presenting cells. To understand how the recipient's MHC class II molecules may influence PLT alloimmunity, immune responsiveness against transfused PLTs was tested in different mouse strains.
STUDY DESIGN AND METHODS: Various inbred and mutant mouse strains were transfused with allogeneic PLTs and IgG donor antibodies were measured by flow cytometry.
RESULTS: When recipient mice, expressing both MHC class II I-A and MHC class II I-E molecules, were transfused weekly with allogeneic PLTs, high titers of IgG donor antibodies were generated. In comparison, however, recipient mice expressing only MHC class II I-A molecules had significantly (p < 0.001) reduced IgG antibody responsiveness against PLT transfusions. The low IgG responder status against allogeneic PLT transfusions was rescued in transgenic mice expressing I-E molecules and in mice genetically deficient in either β2-microglobulin or CD8+ T cells.
CONCLUSION: IgG immune responsiveness against allogeneic PLT transfusions is dependent on recipient expression of I-E MHC class II molecules, whereas I-A expression is linked with CD8-mediated suppression of PLT immunity. The data suggest that strategies to modify recipient MHC class II presentation of donor PLT antigens would be effective in eliminating PLT alloimmunity.
REFERENCES
- 1 Dan ME, Schiffer CA. Strategies for managing refractoriness to platelet transfusions. Curr Hematol Rep 2003; 2: 158-64.
- 2 Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med 1997; 337: 1861-70.
- 3 Sayegh MH, Watschinger B, Carpenter CB. Mechanisms of T cell recognition of alloantigen: the role of peptides. Transplantation 1994; 57: 1295-302.
- 4 Adams PW, Lee HS, Waldman WJ, et al. Alloantigenicity of human endothelial cells. III. Quantitated indirect presentation of endothelial alloantigens to human helper T lymphocytes. Transplantation 1994; 58: 476-83.
- 5 Steele DJ, Laufer TM, Smiley ST, et al. Two levels of help for B cell alloantibody production. J Exp Med 1996; 183: 699-703.
- 6 Parker KE, Dalchau R, Fowler VJ, et al. Stimulation of CD4+ T lymphocytes by allogeneic MHC peptides presented on autologous antigen-presenting cells. Transplantation 1992; 53: 918-24.
- 7 Liu Z, Sun YK, Xi YP, et al. Contribution of direct and indirect recognition pathways to T cell alloreactivity. J Exp Med 1993; 177: 1643-50.
- 8 Lee RS, Grusby MJ, Glimcher LH, et al. Indirect recognition by helper cells can induce donor-specific cytotoxic T lymphocytes in vivo. J Exp Med 1994; 179: 865-72.
- 9 Chen W, Murphy B, Waaga AM, et al. Mechanisms of indirect allorecognition in graft rejection: class II allopeptide-specific T cell clones transfer delayed-type hypersensitivity responses in vivo. Transplantation 1996; 62: 705-10.
- 10 Clement JD, Chan SY, Bishop DK. Allogeneic class I MHC requirement for alloantigen-reactive helper T-lymphocyte responses in vivo: evidence for indirect presentation of alloantigens. Transplantation 1996; 62: 388-96.
- 11 Kao KJ. Effects of leukocyte depletion and UVB irradiation on alloantigenicity of major histocompatibility complex antigens in platelet concentrates: a comparative study. Blood 1992; 80: 2931-7.
- 12 Oh JH, Taysavang P, Whelchel JD. Conferring immunogenicity to platelets by preincubation with recipients’ adherent cells [abstract]. Proceedings of the IX International Congress of Immunology; 1995 Jul 23-29; American Association of Immunologists, San Francisco, CA. p. 69.
- 13 Semple JW, Speck ER, Milev YP, et al. Indirect allorecognition of platelets by T helper cells during platelet transfusions correlates with anti-MHC antibody and cytotoxic T lymphocyte formation. Blood 1995; 86: 805-12.
- 14 Bang A, Speck ER, Blanchette VS, et al. Recipient humoral immunity against leukoreduced allogeneic platelets is suppressed by aminoguanidine, a selective inhibitor of inducible nitric oxide synthase. Blood 1996; 88: 2959-66.
- 15 Bang A, Speck ER, Blanchette VS, et al. Unique processing pathways within recipient antigen-presenting cells determine IgG immunity against donor platelet MHC antigens. Blood 2000; 95: 1735-42.
- 16 Sayeh E, Sterling K, Speck E, Freedman J, Semple JW. IgG antiplatelet immunity is dependent on an early innate natural killer cell-derived interferon-γ response that is regulated by CD8+ T cells. Blood 2004; 103: 2705-9.
- 17 Klein J, Figueroa F, Nagy ZA. Genetics of the major histocompatibility complex: the final act. Annu Rev Immunol 1983; 1: 119-42.
- 18 Cucca F, Lampis R, Congia M, et al. A correlation between the relative predisposition of MHC class II alleles to type 1 diabetes and the structure of their proteins. Hum Mol Genet 2001; 10: 2025-37.
- 19 Burkly LC, Lo D, Brinster RL, et al. I-E transgenic mice: a model system to dissect the regulation and function of MHC class II genes in vivo. Immunol Res 1990; 9: 34-46.
- 20 Levin D, Constant S, Pasqualini T, et al. Role of dendritic cells in the priming of CD4+ T lymphocytes to peptide antigen in vivo. J Immunol 1993; 151: 6742-50.
- 21 Semple JW, Speck ER, Cosgrave D, et al. Extreme leukoreduction of major histocompatibility complex class II positive B cells enhances allogeneic platelet immunity. Blood 1999; 93: 713-20.
- 22 Fast LD. Genotypic regulation of alloantibody production in response to UVB-irradiated allogeneic donor cells. Transfusion 2003; 43: 1295-302.
- 23 Kao KJ. Induction of humoral immune tolerance to major histocompatibility complex antigens by transfusions of UVB-irradiated leukocytes. Blood 1996; 88: 4375-82.
- 24 Ponner BB, Stach C, Zoller O, et al. Induction of apoptosis reduces immunogenicity of human T-cell lines in mice. Scand J Immunol 1998; 47: 343-7.
- 25 Grijzenhout MA, Aarts-Riemens MI, Claas FH, et al. Prevention of MHC-alloimmunization by UV-B irradiation in a murine model: effects of UV dose and number of transfused cells. Br J Haematol 1994; 87: 598-604.
- 26 Williams MA, Trambley J. Genetic characterization of strain differences in the ability to mediate CD40/CD28-independent rejection of skin allografts. J Immunol 2000; 165: 6849-57.
- 27 Murray JS, Schountz T, Ford SR, et al. Modeling alternative binding registers of a minimal immunogenic peptide on two class II major histocompatibility complex (MHC II) molecules predicts polarized T-cell receptor (TCR) contact positions. J Peptide Res 2002; 59: 115-22.
- 28 Benichou G, Valujskikh A, Heeger PS. Contributions of direct and indirect T cell alloreactivity during allograft rejection in mice. J Immunol 1999; 162: 352-8.
- 29 Huber SA, Stone JE, Wagner DH Jr, et al. T cells regulate major histocompatibility complex class II (I-A and I-E)-dependent susceptibility to coxsackievirus B3-induced autoimmune myocarditis. J Virol 1999; 73: 5630-6.
- 30 Ito K, Takeuchi Y, Ito K, et al. Strain-dependent antibody response induced by DNA immunization. Immunol Lett 2000; 74: 245-50.
- 31 Masnaya NV, Churin AA, Borsuk OS, et al. Immune reactions in different mouse strains. Bull Exp Biol Med 2002; 134: 376-8.
- 32 Gustavsson S, Hjulstrom-Chomez S, Lidstrom BM, et al. Impaired antibody responses in H2Ab mice. J Immunol 1998; 161: 1765-71.
- 33 Cosmi L, Liotta F, Lazzeri E, et al. Human CD8+CD25+ thymocytes share phenotypic and functional features with CD4+CD25+ regulatory thymocytes. Blood 2003; 102: 4107-14.
Citing Literature
